Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169866 | 0.83 | MAPT (0.61) | KDM4ERAB9ANPC1MAPTMEN1 | |
| SCHEMBL718330 | 0.80 | HDAC3 (0.61) | KDM4ENPC1MAPTPOLBGAA | |
| SCHEMBL1530164 | 0.78 | KDM4E (0.62) | KDM4EMAPK1PKMRAB9AABCB1 | |
| SCHEMBL22278705 | 0.77 | LMNA (0.55) | KDM4EMAPK1PKMRAB9AABCB1 | |
| SCHEMBL1762404 | 0.77 | MAPK1 (0.63) | KDM4EMAPK1PKMRAB9AABCB1 | |
| SCHEMBL720831 | 0.76 | ABCB1 (0.55) | RAB9AABCB1ABCC1NPC1MAPT | |
| SCHEMBL30436271 | 0.75 | ALDH1A1 (0.47) | KDM4EPKMABCB1ABCC1MAPT | |
| SCHEMBL12468432 | 0.75 | POLB (0.59) | KDM4ERAB9ANPC1MAPTMEN1 | |
| SCHEMBL978546 | 0.75 | MAPT (0.64) | KDM4EMAPK1PKMRAB9AABCB1 | |
| SCHEMBL31331661 | 0.75 | MAPT (0.64) | KDM4EMAPK1PKMRAB9AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381196-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-07-16 | — | — | US | disclosed |
| US-8987468-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE(TGEN (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | HDAC5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC4 | KDM4E 449/4885MAPK1 4387/4885PKM 1209/4885 |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | HDAC5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC4 | KDM4E 449/4885MAPK1 4387/4885PKM 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.